AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02789800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIMAC02
Description: Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
Study NCT04696328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human (allogeneic) iPS cell derived-cardiomyocyte sheet
Description: Transplantation
Study NCT03746340 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
Study NCT03746340 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
Study NCT02894892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (A)Bismuth
Study NCT02894892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (B)Bismuth
Study NCT02894892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (C)Bismuth
Study NCT02894892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (D)Esomeprazole and Bismuth
Study NCT02894892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (E)Esomeprazole and Bismuth
Study NCT02894892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (F)Esomeprazole and Bismuth
Study NCT02894892 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: (G)Control
Study NCT03180021 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers.
Study NCT03151772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: 200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
Study NCT03151772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg x 3 taken preoperatively
Study NCT02918422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
Study NCT03642405 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Samples
Description: Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
Study NCT03642405 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding patients quality of life
Study NCT00718224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection
Study NCT00718224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection
Study NCT00718224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study NCT00718224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study NCT03669172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor IL-15 stimulated NK cells infusion
Description: DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
Study NCT03320954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anomia treatment
Description: Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
Study NCT01773785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
Study NCT01773785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
Study NCT02480023 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: calcaneal quantitative ultrasound assessment
Description: QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
Study NCT03972553 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sugarbaker technique for repairing parastomal hernia
Description: The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
Study NCT03972553 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Keyhole technique for repairing parastomal hernia
Description: The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
Study NCT04347044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Exercise training+ Optimal medication and clinical follow-up
Study NCT04419597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOPATCH
Description: The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
Study NCT04419597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Usual clinical practice techniques for reinforcing primary dural closure.
Study NCT03597789 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Helping the Noncompliant Child (HNC)
Description: HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
Study NCT04114045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental:Whey protein
Description: Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
Study NCT04114045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Isoenergetic control - Carbohydrate
Description: Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
Study NCT04114045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
Study NCT02331654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Description: Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
Study NCT02331654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
Study NCT04347044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart care
Description: Optimal medication and clinical follow-up
Study NCT04347044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standart care
Description: Optimal medication and clinical follow-up
Study NCT01717560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative, multidisciplinary, integrated care
Description: Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management.
Study NCT02324036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMPATHy Toolkit
Description: Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
Study NCT03004027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self help leaflet
Description: Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
Study NCT02324036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coached Care
Description: Community health worker provides participation training to patient
Study NCT04649190 — intervention group
Intervention type: DEVICE
Intervention: TAVI
Description: Coronary access for PCI after TAVI
Study NCT04103203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PathoRobot/ Patho-Doc Test result
Description: Test results of the new diagnostics will be available to the treating physician.
Study NCT03004027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self help leaflet
Description: Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
Study NCT01423058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles.
Study NCT02319889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Undergo SBRT
Study NCT02319889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02319889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02715674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasti-med TRIFLO
Study NCT02715674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP VISION
Study NCT02715674 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plasti-med oxygen therapy mask
Study NCT01990404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed 50% nitrous oxide and oxygen
Description: Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
Study NCT01990404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Description: Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
Study NCT01482884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tralokinumab
Description: 2 sc injections of every 2 weeks for 12 weeks.
Study NCT01482884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 sc injections of every 2 weeks for 12 weeks.
Study NCT04344925 — intervention group
Intervention type: DEVICE
Intervention: Aerosol-reducing Mask
Description: Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
Study NCT04344925 — intervention group
Intervention type: DEVICE
Intervention: Standard Mask
Description: Patient will be put on BIPAP using the standard mask
Study NCT02587715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Description: Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
Study NCT02587715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberation therapy
Study NCT02762123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142 200mg
Study NCT02762123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
Study NCT02762123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142 350mg
Study NCT06138392 — intervention group
Intervention type: DEVICE
Intervention: Dental implant (ELEMENT RC INICELL, Thommen Medical)
Description: Dental implant
Study NCT00498368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Rituximab
Description: Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182
Study NCT00498368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE/ARB
Description: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
Study NCT00498368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE/ARB
Description: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
Study NCT00498368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid Fish Oil Supplement
Description: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
Study NCT00498368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid Fish Oil Supplement
Description: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
Study NCT02909582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cohen Incision
Description: This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
Study NCT02282930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH (Acthar) Gel
Description: Injected dose of 80 units subcutaneously twice weekly for 6 months.
Study NCT00934713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 4mg once per day for 8 weeks period
Study NCT02156206 — intervention group
Intervention type: BEHAVIORAL
Intervention: 123 women emergency phone line in Medellin, Colombia
Description: 123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday.
Study NCT02940899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: Syracuse University Fir Families Program (SUFFP)
Description: The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
Study NCT02015104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
Description: TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
Study NCT02083952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddle Blanket
Description: Two arms involve varying time spent in blanket
Study NCT02015104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC
Description: A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
Study NCT01661504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Screening
Description: The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
Study NCT01642004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01642004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT01986517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No feedback
Description: Therapists will receive no feedback.
Study NCT01986517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback after every fourth session
Study NCT01962389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winsor Laser Catheter
Study NCT00432185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005
Description: 0.25% PEP005 Gel
Study NCT00285649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA-SM
Description: HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
Study NCT02654522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: 1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
Study NCT02063022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (as per protocol ISG SSG III)
Description: Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)